
D&D Pharmatech Announces Rapid, Clinically Significant Reductions in Liver Fat Achieved in Four Weeks Treating NAFLD Patients with DD01, a Novel Long-Acting GLP-1/Glucagon Receptor Agonist
– Study results demonstrate DD01 was safe and well-tolerated at doses highly effective in reducing fatty liver. – Following only 4 weeks of treatment, all […]













